Rectal motility in pediatric constipation

Iben Moeller Joensson1, Soren Hagstroem, Lotte Fynne

  • 1*Institute of Clinical Medicine, University of Aarhus †Department of Pediatrics, Aarhus University Hospital, Skejby ‡Neurogastroenterology Unit, Department of Hepatology and Gastroenterology V, Aarhus University, Hospital, Aarhus, Denmark.

Insights

Children with constipation exhibit prolonged rectal contractions and larger rectal dimensions compared to healthy children. This study utilized rectal impedance planimetry to assess rectal motility and size in pediatric constipation.

Area of Science:

  • Pediatric Gastroenterology
  • Gastrointestinal Motility Research
  • Clinical Physiology

Background:

  • Childhood constipation is a prevalent condition with unclear etiological factors.
  • Rectal impedance planimetry offers detailed insights into rectal cross-sectional area (CSA) and pressure, crucial for understanding rectal motility.

Purpose of the Study:

  • To investigate and compare rectal motility patterns between children experiencing constipation and healthy children.
  • To characterize differences in rectal dimensions and compliance using rectal impedance planimetry.

Main Methods:

  • The study involved 10 constipated children (Rome III criteria) and 10 healthy children, aged 8.8 and 9.9 years, respectively.
  • Rectal impedance planimetry measured CSA at three levels, recorded resting motility for 30 minutes, and assessed compliance via distension.
  • Phasic rectal contractions were defined as >10% CSA change from baseline for at least 2 minutes.

Main Results:

  • Constipated children showed significantly longer durations of phasic rectal contractions (median 38%) compared to healthy children (median 8.8%).
  • Rectal CSA was significantly larger in constipated children (median 1802 mm²) versus healthy children (median 1375 mm²).
  • Rectal compliance did not significantly differ between the two groups.

Conclusions:

  • Children with constipation demonstrate a prolonged period of phasic rectal contractions.
  • Constipated children exhibit larger rectal dimensions than their healthy counterparts.
  • These findings suggest altered rectal motility and size contribute to pediatric constipation.
Abstract

Related Concept Videos

Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.6K
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
1.6K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.5K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
923
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
2.0K